Pharmacokinetic-pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens

Food and Chemical Toxicology

Volumn 49, Issue 7, 2011, Pages 1530-1536

  Haritova, Aneliya ^a   Urumova, Valentina ^a   Lutckanov, Mihni ^a   Petrov, Vladimir ^a   Lashev, Lubomir ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

Chicken; E. coli infection; Enrofloxacin; Quercetin

Indexed keywords

CIPROFLOXACIN; DRUG METABOLITE; ENROFLOXACIN; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CHICKEN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG TRANSFORMATION; ESCHERICHIA COLI INFECTION; HEART; INOCULATION; LIVER; LOW DRUG DOSE; LUNG; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; NONHUMAN; PREDICTIVE VALUE; SPLEEN;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; CHICKENS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; QUERCETIN; TISSUE DISTRIBUTION;

ANIMALIA; ESCHERICHIA COLI; GALLUS GALLUS;

EID: 79957662238     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.03.044     Document Type: Article

References (39)

1. Anadon A., Martinez-Larranaga M.R., Diaz M.J., Bringas P., Martinez M.A., Fernandez-Cruz M.L., Fernandez M.C., Fernandez R. Pharmacokinetics and residues of enrofloxacin in chickens. Am. J. Vet. Res. 1995, 56:501-506.
2. Barrenetxe J., Aranguren P., Grijalba A., Martinez-Penuela J., Marzo F., Urdaneta E. Effect of dietary quercetin and sphingomyelin on intestinal nutrient absorption and animal growth. Br. J. Nutr. 2006, 95:455-461.
3. Bischoff S.C. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care. 2008, 11:733-740.
4. Carreras I., Castellari M., Garci{dotless}a Regueiro J.A., Guerrero L., Esteve-Garcia E., Sarraga C. Influence of enrofloxacin administration and α-tocopheryl acetate supplemented diets on oxidative stability of broiler tissues. Poult. Sci. 2004, 83:796-802.
5. Cermaka R., Weinb S., Wolffram S., Langguthc P. Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur. J. Pharm. Sci. 2009, 38:519-524.
6. Charleston B., Gate J.J., Aitken I.A., Stephan B., Froyman R. Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens. Antimicrob. Agents Chemother. 1998, 42:83-87.
7. Ciu J., Liu Y., Wang R., Tong W., Drlica K., Zhao X. The mutant selection window in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 2006, 194:1601-1608.
8. CLSI, Clinical and Laboratory Standards Institute, 2008. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard-Third Edition. CLSI document M31-A3. Wayne, Pennsylvania, USA.
9. Cushnie T.P., Lamb A.J. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents. 2005, 26:343-356.
10. Dimitrova D.J., Lashev L.D., Yanev S.G., Pandova B. Pharmacokinetics of enrofloxacin in turkeys. Res. Vet. Sci. 2007, 82:392-397.
11. Dupuy J., Larrieu G., Sutra J.F., Lespine A., Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 2003, 112:337-347.
12. Ferran A.A., Kesteman A.S., Toutain P.L., Bousquet-Mélou A. Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrob. Agents Chemother. 2009, 53:3384-3390.
13. Frazier D.L., Thompson L., Trettien A., Evans E.I. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J. Vet. Pharmacol. Therap. 2000, 23:293-302.
14. Garcia M.A., Solans C., Aramayona J.J., Rueda S., Bregante M.A. Development of a method for the determination of danofloxacin in plasma by HPLC with fluorescence detection. Biomed. Chromatogr. 2000, 14:89-92.
15. Giovanardi D., Campagnari E., Ruffoni S.L., Pesente P., Ortali G., Furlattini V. Avian pathogenic Escherichia coli transmission from broile breeders to their progeny in an integrated poultry production chain. Avian Pathol. 2005, 34:313-318.
16. Gutierrez O.L., Sumano L.H., Zamora Q.M. Administration of enrofloxacin and capsaicin to chickens to achieve higher maximal serum concentrations. Vet. Rec. 2002, 150:350-353.
17. Haritova A., Rusenova N. In vitro antibacterial effect of enrofloxacin determined by time-killing curves analysis. Bulg. J. Vet. Med. 2010, 13(4):218-226.
18. Haritova A., Djeneva H., Lashev L., Sotirova P., Gurov B., Dyankov V., Stefanova M. Pharmacokinetics and PK/PD modelling of enrofloxacin in Meleagris gallopavo and Gallus domesticus. Bulg. J. Vet. Med. 2004, 7:139-148.
19. Haritova A., Rusenova N., Parvanov P., Lashev L., Fink-Gremmels J. Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys. Vet. Res. Commun. 2006, 30:775-789.
20. Haritova A., Rusenova N., Parvanov P., Lashev L., Fink-Gremmels J. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys. Antimicrob. Agents. Chemother. 2006, 50:3779-3785.
21. Hsiu S.-L., Hou Y.-C., Wang Y.-H., Tsao C.-W., Su S.-F., Chao P.-D.L. Quercetin significantly decreased cyclosporine oral bioavailability in pigs and rats. Life Sci. 2002, 72:227-235.
22. Huff W.E., Huff G.R., Rath N.C., Balog J.M., Donoghue A.M. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult. Sci. 2004, 83:1944-1947.
23. Kesteman A.S., Ferran A.A., Perrin-Guyomard A., Laurentie M., Sanders P., Toutain P.L., Bousquet-Mélou A. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model. Antimicrob. Agents Chemother. 2009, 53:4740-4748.
24. Kesteman A.S., Ferran A.A., Perrin-Guyomard A., Laurentie M., Sanders P., Toutain P.L., Bousquet-Mélou A. Impact of marbofloxacin dosing regimen on intestinal flora in a dixenic rat model with Klebsiella pneumoniae lung infection. J. Vet. Pharmacol. Therap. 2009, 32(Suppl. 1):163.
25. Knoll U., Glunder G., Kietzmann M. Comparative study of the pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. J. Vet. Pharmacol. Therap. 1999, 22:239-246.
26. McKellar Q.A., Sanchezbruni S.F., Jones D.G. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J. Vet. Pharmacol. Therap. 2004, 27:503-514.
27. Moon Y.J., Marilyn X.W., Morris E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro 2006, 20:187-210.
28. Nair M.P., Mahajan S., Reynolds J.L., Aalinkeel R., Nair H., Schwartz S.A., Kandaswami C. The flavonoid quercetin inhibits proinflammatory cytokine (Tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-system. Clin. Vaccine Immunol. 2006, 13:319-328.
29. Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., Langguth P. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?. Eur. J. Pharm. Sci. 2005, 25:263-271.
30. Pal D., Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006, 78:2131-2145.
31. Patel J., Buddha B., Dey S., Pal D., Mitra A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in Pgp and CYP3A4 activity. Am. J. Ther. 2004, 11:262-277.
32. Plaper A., Golob M., Hafner I., Oblak M., Solmajer T., Jeralab R. Characterization of quercetin binding site on DNA gyrase. Biochem. Biophys. Res. Commun. 2003, 306:530-536.
33. Rao G.S., Ramesh S., Ahmad A.H., Tripathi H.C., Sharma L.D., Malik J.K. Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. J. Vet. Pharmacol. Therap. 2000, 23:365-372.
34. Rusenova N., Haritova A., Parvanov P. Influence of cyclosporine A and quercetine on MIC values of danofloxacin mesylate in E. coli strains isolated from poultry. Turk. J. Vet. Animal Sci. 2009, 33:247-251.
35. Shin S.-C., Choi J.-S., Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm. 2006, 313:144-149.
36. Sumano L.H., Gutierrez O.L., Zamora Q.M. Strategic administration of enrofloxacin in poultry to achieve higher maximal serum concentrations. Vet. J. 2003, 165:143-148.
37. White D.G., Piddock L.J.V., Maurer J.J., Zhao S., Ricci V., Thayer S.G. Characterization of fluoroquinolone resistance among veterinary isolates of avian Escherichia coli. Antimicrob. Agents Chemother. 2000, 44:2897-2899.
38. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 2001, 33(Suppl. 3):S147-S156.
39. Zhang J.-W., Liu Y., Cheng J., Li W., Ma H., Liu H.-T., Sun J., Wang L.-M., He Y.-Q., Wang Y., Wang Z.-T., Yang L. Inhibition of human liver cytochrome P450 by star fruit juice. J. Pharm. Pharmaceut. Sci. 2007, 10:496-503.